The Biosynthesis of Cholesterol

The biosynthesis of cholesterol as outlined in Figure 26 10 is admittedly quite complicated It will aid your understanding of the process if you consider the following questions... 

Squalene epoxidase, a key enzyme in the biosynthesis of cholesterol (9), epoxidizes one face of one of the three different olefins in squalene (7) to give squalene epoxide (8), which then cyclizes eventually to give cholesterol (9) (Scheme 1). The AD of squalene (7)... 

The biosynthesis of cholesterol may be divided into five steps (l) Synthesis of mevalonate occurs from acetyl-CoA (Figure 26-1). (2) Isoprenoid units are formed... 

Fiandanese and coworkers [103] described a new approach for the synthesis of the butenolides xerulin (6/1-207) and dihydroxerulin (6/1-208), which are of interest as potent noncytotoxic inhibitors of the biosynthesis of cholesterol (Scheme 6/1.53). The key transformation is a Pd°-catalyzed Sonogashira/addition process of 6/1-204 or 6/1-206 with (Z)-3-iodo-2-propenoic acid 6/1-205, which is followed by the formation of a lactone to give 6/1-207 and 6/1-208, respectively. 

An enzyme (see Section 2.6) called HMG-CoA reductase is involved in the biosynthesis of cholesterol. Drugs such as atorvastatin (Lipitor) and simvastatin (Zocor) are competitive inhibitors of HMG-CoA reductase. They inhibit cholesterol synthesis by increasing the number of LDL receptors to take up the LDL. 

Competitive blocker of a-adrenergic receptors in heart and blood vessels Inhibits the enzyme HMG-CoA reductase and reduces the biosynthesis of cholesterol Acts as an angiotensin II receptor antagonist Inhibits the synthesis of prostaglandins via the selective inhibition of the enzyme cyclooxygenase-2... 

Cholesterol is one of the isoprenoids, synthesis of which starts from acetyl CoA (see p. 52). In a long and complex reaction chain, the C27 sterol is built up from C2 components. The biosynthesis of cholesterol can be divided into four sections. In the first (1), mevalonate, a Ce compound, arises from three molecules of acetyl CoA. In the second part (2), mevalonate is converted into isopen-tenyl diphosphate, the active isoprene. In the third part (3), six of these C5 molecules are linked to produce squalene, a C30 compound. Finally, squalene undergoes cycliza-tion, with three C atoms being removed, to yield cholesterol (4). The illustration only shows the most important intermediates in biosynthesis. 

The statins are considered as a major breakthrough in the development of hypolipaemic drugs. These agents inhibit the biosynthesis of cholesterol (Fig. 8) and also increase the density of LDL-receptors. They induce a potent lowering of total cholesterol, LDL, and a weak lowering effect on the triglycerides. The plasma HDL-cholesterol level is moderately enhanced. 

Fig. 8. Most important steps in the biosynthesis of cholesterol. The reduction of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) to yield mevalonic acid is an important rate-limiting step and also the site of attack of the HMG-CoA-reductase inhibitors (statins).

Figure 7.66 Trifluoromethyl alcohols and ketones as inhibitors of the biosynthesis of cholesterol.

Trifluoromethyl ketones and alcohol derivatives of squalene have been prepared in order to inhibit squalene epoxycyclase. This important enzyme regulates the biosynthesis of cholesterol. It bears a cysteine in its active site. Although these compounds have been shown to be good inhibitors, the involved mechanism is different from what was expected. Indeed, they do not inhibit squalene epoxycyclase, but they are substrates of this enzyme and are transformed into fluorohydroxysterols. The repression of the expression of HMG-CoA reductase is responsible for the observed inhibition of cholesterol biosynthesis. This repression comes from the back-regulation that is exerted by fluorohydroxysterols. Indeed, these compounds induce an important diminution of the cell activity of HMG-CoA reductase (Figure 7.66). °... 

We begin with an account of the main steps in the biosynthesis of cholesterol from acetate, then discuss the transport of cholesterol in the blood, its uptake by cells, the normal regulation of cholesterol synthesis, and its regulation in those with defects in cholesterol uptake or transport. We next consider other cellular components derived from cholesterol, such as bile acids and steroid hormones. Finally, an outline of the biosynthetic pathways to some of the many compounds derived from isoprene units, which share early steps with the pathway to cholesterol, illustrates the extraordinary versatility of isoprenoid condensations in biosynthesis. 

Compound MC-033 (205), structurally similar to chlorothricin, has been isolated from a cultured broth of Streptomyces sp., and inhibits the biosynthesis of cholesterol from mevalonate with an IC50 value of 1.05 x 10° M [163]. 

Work on the biosynthesis of cholesterol began in earnest after Rudolf Schoenheimer and David Rittenberg, at Columbia University, developed isotopic tracer techniques for the analysis of biochemical pathways. In 1941, Rittenberg and Konrad Bloch were able to show that deuterium-labeled acetate (C2H, COO ) was a precursor of cholesterol in rats and mice. In 1949, James Bonner and Barbarin Arreguin postulated that three acetates could combine to form a single five-carbon unit called isoprene. 

This proposal supported, with an earlier prediction of Sir Robert Robinson, that cholesterol was a cyclization product of squalene, a 30-carbon polymer of isoprene units. In 1953, Robert Bums Woodward and Bloch postulated a cyclization scheme for squalene (fig. 20.2) that was later shown to be correct. In 1956, the unknown isoprenoid precursor was identified as mevalonic acid by Karl Folkers and others at Merck, Sharpe, and Dohme Laboratories. The discovery of mevalonate provided the missing link in the basic outline of cholesterol biosynthesis. Since that time, the sequence and the stereochemical course for the biosynthesis of cholesterol have been defined in detail. 

Figs. 12—16 to 12—22) and prevent the progressive course of Alzheimer s disease. Direct inhibition of gene expression for the biosynthesis of these proteins is not currently possible and is currently not a very feasible therapeutic possibility. Perhaps a more realistic therapeutic possibility would be to inhibit the synthesis of beta amyloid, in much the same way that lipid-lowering agents act to inhibit the biosynthesis of cholesterol in order to prevent atherosclerosis. This could be done by means of enzyme inhibitors, such as protease inhibitors, which are at least a theoretical possibility. 

In the biogenesis of steroids, the enzyme-catalyzed polycyclization of squalene (225) produces the tetracyclic substance lanosterol (225) which is eventually converted into cholesterol (227) Eschenmoser, Stork, and their co-workers (80-82) have proposed that the squalene-1anosterol conversion can be rationalized on the basis of stereoelectronic effects. The stereochemical course of this biological cyclization (83, 84) can be illustrated by considering the transformation of squalene oxide (228) (an intermediate in the biosynthesis of cholesterol (83, 84)) into dammaradienol 229. This transfor-... 

After screening 8000 microorganisms, three novel inhibitors of HMG-CoA reductases were found at Sankyo (Tokyo, Japan), Mevastatin among them. The open form inhibits HMG-CoA reductase with a K value of 1 nM and influences dramatically the biosynthesis of cholesterol, just like the later developed analogs Lovastatin and Simvastatin (Figure 13.15, below). 

Some of the most exciting natural products discovered in recent years are the cholesterollowering agents derived from fungi. These drugs inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-COA reductase), an enzyme critical in the biosynthesis of cholesterol. The first HMG-COA reductase inhibitors were isolated from Pencillium sp. 

One class of antihyperlipidemic drugs is the statins. Statins interfere with the biosynthesis of cholesterol (A.103) and specifically inhibit the enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (Scheme A.l). The statins that have been approved by the FDA include lovastatin (Mevacor, A.104), simvastatin (Zocor, A.105), pravastatin (Prava-chol, A.106), atorvastatin (Lipitor, A.107), rosuvastatin (Crestor, A.108), and fluvastatin (Lescol, A.109) (Figure A.29). All six compounds are drawn here to highlight the similarities between HMG-CoA (A.99) and mevalonic acid (A.100), and the top portion of the various statins. As a class, the statins have been extremely successful in terms of sales and effective in decreasing LDL cholesterol levels in the blood. 

Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway (Fig. 1). In contrast to desmosterol and other late-stage lipid-soluble intermediates, HMG is water-soluble, and there are alternative metabolic pathways for its breakdown when HMG-CoA reductase is inhibited so that there is no buildup of potentially toxic precursors. Therefore, of the more than 30 enzymes involved in the biosynthesis of cholesterol, HMG-CoA reductase was a natural target. Substances that have a powerful inhibitory effect on this enzyme, including ML236B (compactin), were first discovered by Endo in a fermentation broth of Penicillium citrinum in the... 

All the major biosynthetic pathways use acetyl-CoA as the basic building block, and in each pathway the rate limiting enzyme is regulated by phosphorylation with the phosphorylated enzyme being active. In the biosynthesis of cholesterol, the rate limiting step is catalyzed by hydroxymethylglutaryl-CoA (HMG-CoA) reductase. Initially, three molecules of acetyl-CoA are condensed to produce /5-HMG-CoA. HMG-CoA reductase then uses two NADPH molecules to reduce HMG-CoA to mevalonate-CoA. The remaining steps in cholesterol biosynthesis are numerous and well-documented. 

Understand the biosynthesis of cholesterol compare this process with that of ketone body production know what controls cholesterol biosynthetic reactions. 

The biosynthesis of cholesterol begins with acetyl-CoA in what is a very complex process involving 32 different enzymes, some of which are soluble in the cytosol and others of which are bound to the ER membrane. The basic carbon building block of cholesterol is isoprene (Chap. 6). 

---